TP53 Arg72Pro Gene Polymorphism in Patients with Malignant Head and Neck Tumors

Ashot D. Dadamov, PhD*

Tashkent Medical Academy, Tashkent, Uzbekistan


Several studies have shown that the Arg72Pro TP53 gene polymorphism is associated with an increased risk of malignancies. The aim of this study is to investigate the distribution of the genotypes of Arg72Pro TP53 gene polymorphism in patients with malignant tumors of the head and neck (MTHN). The study involved 117 patients including 90 males and 27 females, of mean age 54.3±8.6, having MTHN. The control group consisted of 70 Uzbek volunteers (mean age 51.0±6.2 years) without malignant tumors. The frequency of the distribution of the genotypes of Arg72Pro TP53 polymorphism in patients having MTHN included Arg/Arg - 0.1, Arg/Pro - 0.68, Pro/Pro - 0.20; χ2=99.308, p=0.000. In healthy volunteers the ratio of Arg/Arg: Arg/Pro: Pro/Pro was found to be 0.27:0.52:0.20; χ2=21.57, p=0.000. The heterozygous genotype was dominant in the patients with MTHN, as well as those in the control group. However, the findings were significantly higher in the study group, viz., 0.68 as against 0.52 in the control group (p=0.03). The homozygous genotype Arg/Arg was rarely encountered in the patients, viz., 0.11 in the study group compared with 0.27 in the control group (p=0.005). The risk of being an MTHN carrier was found to be associated with the polymorphic marker gene TP53, and particularly, with the accumulation of the Arg/Pro genotype [OR: 1.93 (95% CI: 1.05-3.55)], while reducing the frequency of the Arg/Arg genotype [OR: 0.34 (95% CI: 0.15-0.73)]. 

Arg72Pro TP53 gene polymorphism; Uzbek patients; malignant tumors of the head and neck.
  1. Thiagalingam SA. Cascade of modules of a network defines cancer progression. Cancer Res 2006; 66 (15):7379—7385.
  2.  Weinberg RA. Mechanisms of malignant progression. Carcinogenesis 2008; 29:1092-1105.
  3. Gupta PB, Chaffer CL, Weinberg RA. Cancer stem cells: mirage or reality. Nat Med 2009; 15:1010-1012.
  4.  Imyanitov  Ye N. Molecular mechanisms of tumor growth. Voprosy onkologii 2010; 2:117-128.
  5.  Levine AJ. P53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-331.
  6.  Matlashewski G, Lamb P, Pim D, Peacock J, Crawford L, Benchimol S. Isolation and characterization of a human p53 cDNA clone: Expression of the human p53 gene. EMBO J 1984; 3: 3257-3262.
  7. Olivier M, Petitjean A, Marcel V, Petre A, Mounawar M. Recent advances in p53 research: An interdisciplinary perspective. Cancer Gene Ther 2009; 16:1-12.
  8. Petitjean A, Achatz MIW, Borresen-Dale AL, Hainaut P, Olivier M. TP53 mutations in human cancers: Functional selection and impact on cancer prognosis and outcomes. Oncogene 2007; 26: 2157-2165.
  9.  Pop C, Timers J, Salvesen S. The apoptosome activates caspase-9 by dimerisation. Molecular Cell 2006; 22:269-275.
  10. Bond GL, Levine AJ. A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stress and tumor genetics to influence cancer in human. Oncogene 2007; 26:1317-1323.
  11. Lopes-Otin C, Matrisian LM. Emerging roles of proteases in tumor suppression. Nat Rev Cancer 2007; 7: 800-808.
  12. Zache N, Lambert J, Wiman KG, Bykov V. PRIMA - 1 inhibits growth of mouse  tumor carrying mutant  p53. Cellular Oncology 2008; 30 (5): 411-418.
  13. Mitra S, Sikdar N, Misra C, et al. Risk assessment of p53 genotypes and haplotypes in tobacco-associated leukoplakia and oral cancer patients from eastern India.  Int J Cancer 2005; 117(5): 786-793.
  14. Bouchet BP, De Fromentel CC, Puisieux A, Galmarini CM. P53 as a target for anti-cancer drug development. Critical Reviews in Oncology. Hematology 2006; 58:190–202.              
  15. Nguyen DX, Massaque J. Genetic determinants of cancer metastasis.  Nat Rev Genet, 2007;  8:341-352.
  16.  Lambert J.  Mutant p53 reactivation by PRIMA-1, molecular mechanism and biological effects. Carolinska institutet, Stockholm, 2008.
  17. Kashiwasaki H, Hassan N, Hamada J, Morinchi T, et al. Gene expression profile changes correlated with lymph node metastasis in oral squamous cell carcinoma. Odontology 2008; 96(1):38-43.
  18. Yamazaki Y, Chiba I, Ishikawa M, Sato Ch, et al. Serum p53 antibodies as a prognostic indicator in oral squamous cell carcinoma. Odontology 2008; 96(1):32-37.    
  19. Petti S, Scully C. Determinants of oral cancer of the national level: just a question of smoking and alcohol drinking prevalence. Odontology 2010; 98(2):144-152.
  20. Pietsch EC, Humbey O, Murphy ME. Polymorphisms in the p53 pathway. Oncogene 2006; 25: 1602-1611. P.
  21. Olivier M, Hainaut P, Borresen-Dale AL. Prognostic and Predictive Value of TP53 Mutations in Human Cancer. In: 25 Years of p53 Research Hainaut, P. and K.G. Wiman, Springer-Verlag. Netherlands, 2006.
  22.  Perfumo C, Bonelli L, Menichini P, Inga A, Gismondi V. Increased risk of colorectal adenomas in Italian subjects carrying the p53 PIN3 A2-Pro72 haplotype. Digestion 2006; 74: 228-235.
  23. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 1999; 19: 1092-1100.
  24. Bonafe M, Salvioli M, Barbi C, et al. The different apoptotic potential of the p53 codon 72 alleles   increases with age and modulates in vivo ischemia-induced cell death. Cell Death.Differ 2004; 11 (9): 962 - 973.
  25. Sallivan A, Syed N, Gasco M, et al. Polymorphism in wild type p53 modulates response to chemotherapy in vitro and in vivo.  Oncogene 2004; 23 (19):3328 - 3337.
  26. Shi H, Lambert J, Heitefeuille A, Bykov V, et al. In vitro and in vivo cytotoxic effects of PRIMA-1 on hepatocellular carcinoma cells expressing mutant p53ser249. Carcinogenesis 2008; 29 (7):1428-1434. 
  27. Hsieh LL, Chien HT, Chen IH, Liao CT, Wang HM, et al. The XRCC1399Gln polymorphism and the frequency of p53 mutations in Taiwanese oral squamous cell carcinomas. Cancer Epidemiol Biomarkers Prev 2003; 12(5): 439-443.
  28. Sainger RN, Shah MH, Desai AA, Shukla PM, Shah PM, et al. Clinical significance of serum p53 antibodies in oral cancer. Tumori 2006; 92:134-139.
  29. Lai KC, Chang KW. Liu CJ, Kao SY, Lee TC. IFN- induced protein with tetrotricopeptide  repeats 2 inhibits migration activity and increases survival of oral squamous cells. Molec Cancer Research 2008; 6 (9):1431-1439. 
  30. Hoekstra JW, Kummer JA, van Es RJ. Late (> 5 years) regional  lymph node metastasis of oral squamous cell carcinoma , proven by p53 mutation analysis. J Craniomaxillofac Surg 2008; 36: 415-418.

Download Article

Int J Biomed. 2011; 1(4):217-220. © 2011 International Medical Research and Development Corporation. All rights reserved.